1. Home
  2. DGHI vs IMAB Comparison

DGHI vs IMAB Comparison

Compare DGHI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DGHI
  • IMAB
  • Stock Information
  • Founded
  • DGHI 2017
  • IMAB 2014
  • Country
  • DGHI United States
  • IMAB United States
  • Employees
  • DGHI N/A
  • IMAB N/A
  • Industry
  • DGHI Finance: Consumer Services
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • DGHI Finance
  • IMAB Health Care
  • Exchange
  • DGHI Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • DGHI 90.1M
  • IMAB 79.9M
  • IPO Year
  • DGHI N/A
  • IMAB 2020
  • Fundamental
  • Price
  • DGHI $3.07
  • IMAB $0.97
  • Analyst Decision
  • DGHI Strong Buy
  • IMAB Strong Buy
  • Analyst Count
  • DGHI 1
  • IMAB 3
  • Target Price
  • DGHI $2.50
  • IMAB $8.00
  • AVG Volume (30 Days)
  • DGHI 874.7K
  • IMAB 280.2K
  • Earning Date
  • DGHI 04-02-2025
  • IMAB 03-13-2025
  • Dividend Yield
  • DGHI N/A
  • IMAB N/A
  • EPS Growth
  • DGHI N/A
  • IMAB N/A
  • EPS
  • DGHI N/A
  • IMAB N/A
  • Revenue
  • DGHI $42,146,057.00
  • IMAB $3,313,984.00
  • Revenue This Year
  • DGHI N/A
  • IMAB N/A
  • Revenue Next Year
  • DGHI N/A
  • IMAB N/A
  • P/E Ratio
  • DGHI N/A
  • IMAB N/A
  • Revenue Growth
  • DGHI 100.56
  • IMAB N/A
  • 52 Week Low
  • DGHI $0.84
  • IMAB $0.84
  • 52 Week High
  • DGHI $3.77
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • DGHI 59.08
  • IMAB 43.19
  • Support Level
  • DGHI $2.81
  • IMAB $1.03
  • Resistance Level
  • DGHI $3.35
  • IMAB $1.10
  • Average True Range (ATR)
  • DGHI 0.49
  • IMAB 0.06
  • MACD
  • DGHI -0.01
  • IMAB -0.01
  • Stochastic Oscillator
  • DGHI 43.36
  • IMAB 7.58

About DGHI Digihost Technology Inc. Common Subordinate Voting Shares

Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: